Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_4
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
completed

Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

NCT01304238
terminatedphase_1

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

NCT00003726
terminatedphase_4

Argatroban Versus Lepirudin in Critically Ill Patients

NCT00798525
completedphase_2

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices

NCT00039767

Clinical Trials (4)

Showing 4 of 4 trials
NCT01304238

Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

Completed
NCT00003726Phase 1

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

Terminated
NCT00798525Phase 4

Argatroban Versus Lepirudin in Critically Ill Patients

Terminated
NCT00039767Phase 2

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4